Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Purdue Pharma LP late Tuesday announced the elimination of its entire sales force and creation of a new business model focused less heavily on narcotic painkillers, a milestone development for the country’s most notorious seller of prescription opioids.
The Trump administration and Congress are tightening investment restrictions and export controls to address technology transfer concerns. These measures initially focus on China, but will have broader effects on investments in the United States and transfers of emerging technologies, say attorneys with Baker McKenzie.
A recent report by the U.S. Government Accountability Office highlights the important role corporate integrity agreements play in protecting federal health care programs when federal laws are violated. Given their central role in promoting compliance, it is time for the U.S. Department of Health and Human Services’ Office of Inspector General to update its templates and approach, say attorneys with Skadden Arps Slate Meagher & Flom LLP.
Former executives at Aegerion Pharmaceuticals Inc. argued Tuesday that a False Claims Act case against them ignores a federal regulatory program that gave marketers and doctors explicit permission to recommend an expensive cholesterol drug to people who did not have the rare genetic disorder it was created for.
Two former biostatistician friends at Akebia Therapeutics Inc. and Merrimack Pharmaceuticals Inc. will face securities fraud charges for allegedly cashing in on nonpublic drug trial information, a federal judge in Massachusetts said Tuesday.